| Full text | |
| Author(s): |
Terzian, Ana C. B.
;
Azar, Sasha R.
;
Estofolete, Cassia F.
;
Nogueira, Mauricio L.
;
Vasilakis, Nikos
Total Authors: 5
|
| Document type: | Journal article |
| Source: | VACCINES; v. 12, n. 12, p. 8-pg., 2024-12-01. |
| Abstract | |
Background/Objectives: Yellow fever virus (YFV) (Flaviviridae, Orthoflavivirus) is the etiologic agent of yellow fever (YF), a vector-borne disease with significant morbidity and mortality across the tropics and neotropics, despite having a highly efficacious and safe vaccine (17D). Vaccination provides lifelong protection from YF disease mediated by humoral immunity. There are several versions of the original 17D vaccine: 17D-204 (marketed in the USA as YF-VAX, in France as Stamaril, and in China as Tiantan-V), 17D-213 (Russian Federation), and 17DD (by FIOCRUZ in Brazil). Vaccines produced in the US, France, Senegal, China, and Russia represent 17D-204-derived strains, whereas the Brazilian 17DD has a unique passage/attenuation history from 17D-204-derived strains. Their functional differences in the neutralization profiles are not known. Methods: The Plaque Reduction Neutralization Test (PRNT) was used to determine the neutralization profiles of sera from 209 patients that were previously vaccinated with the 17DD strain against both 17D-204 and 17DD. Results: Sera exhibited significantly more efficient neutralization of 17DD (mean reciprocal PRNT50 183, PRNT80 86, median reciprocal PRNT50 80, and PRNT80 40) compared to 17D-204 (mean reciprocal PRNT50 91, PRNT80 33, median reciprocal PRNT50 40, and PRNT80 10). Conclusions: Our data indicate antigenic differences between 17D and 17DD vaccines. (AU) | |
| FAPESP's process: | 22/03645-1 - Study of the virus-vector interaction and the mechanisms involved in modulating the dynamics of viral transmission |
| Grantee: | Maurício Lacerda Nogueira |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 22/09229-0 - Influence of previous exposure to Zika Virus on acute Dengue infection: epidemiological, clinical, immunological, and virological aspects |
| Grantee: | Cássia Fernanda Estofolete |
| Support Opportunities: | Regular Research Grants |